Keeping an eye on monitoring

Philippe Dro previously served as CEO of GlycoVaxyn AG, a Swiss biotech startup in vaccines, which was acquired by GSK in early 2015. Before GlycoVaxyn, Dro was CEO of EndoArt SA, a medical technology company spin-out from the École polytechnique fédérale de Lausanne (EPFL), which was acquired by Allergan in early 2007. Dro holds a PhD in pharmacy from the University of Grenoble as well as an MBA  from Ecole Superieure de Commerce de Lyon and Cranfield School of Management in the United Kingdom.